ALKERMES, INC. for ALKERMES, INC.

Medicare/Medicaid MMM

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase-in for small companies;

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Health Issues HCR

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP); Natl Institutes of Health (NIH)

Bills named: H.R. 2163 (119th), H.R. 946 (119th), S. 464 (119th), H.R. 1414 (119th)

Alcohol and Drug Abuse ALC

Expand funding and flexibility to address all substance use disorders;

Contacted: Justice, Dept of (DOJ); SENATE; Executive Office of the President (EOP); Veterans Affairs, Dept of (VA); Substance Abuse & Mental Health Services Administration (SAMHSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)